Legislation intended to prevent concentration changes from blocking biosimilar entry has the potential to upend the interchangeability system, which may be why stakeholders argue it needs some tweaks.
The US Food and Drug Administration has interpreted the definition of biosimilarity to mean that the strength or concentration of the biosimilar must be the same as the reference product, along with